Abstract
Failures in trials for Alzheimer's disease (AD) may be attributable to inadequate dosing, population selection, drug inefficacy, or insufficient design optimization. The Coalition Against Major Diseases (CAMD) was formed in 2008 to develop drug development tools (DDT) to expedite drug development for AD and Parkinson's disease.1 CAMD led a process that successfully advanced a clinical trial simulation (CTS) tool for AD through the formal regulatory review process at the US Food and Drug Administration (FDA) and European Medicines Agency (EMA).
Original language | English |
---|---|
Pages (from-to) | 210-214 |
Number of pages | 5 |
Journal | Clinical Pharmacology and Therapeutics |
Volume | 97 |
Issue number | 3 |
DOIs | |
State | Published - Mar 2015 |
Externally published | Yes |